Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026
Ascendis Pharma A/S - American Depositary Shares (ASND)
Last ascendis pharma a/s - american depositary shares earnings: 11/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ascendispharma.com
Company Research
Source: GlobeNewswire
COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday, February 11, 2026, after the close of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on February 11, 2026, at 4:30 p.m. Eastern Time (ET) to discuss 2025 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com. A replay of the webcast will be available on this section of the Ascendis Pharma website shortly after the conclusion of the event for 30 days. About Ascendis Pharma A/S Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma co
Show less
Read more
Impact Snapshot
Event Time:
ASND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASND alerts
High impacting Ascendis Pharma A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ASND
News
- Pendopharm Announces the Approval of Yorvipath® (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in Adults [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at Bank of America Corporation from $246.00 to $260.00. They now have a "buy" rating on the stock.MarketBeat
- RBC Maintains Outperform Rating on Ascendis Pharma (ASND) Amid Growth Targets [Yahoo! Finance]Yahoo! Finance
- Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.MarketBeat
- Ascendis Pharma A/S (NASDAQ:ASND) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.MarketBeat
ASND
Earnings
- 11/12/25 - Miss
ASND
Sec Filings
- 2/3/26 - Form SCHEDULE
- 1/14/26 - Form 6-K
- 1/13/26 - Form 144
- ASND's page on the SEC website